Opendata, web and dolomites

CORolla

"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CORolla project word cloud

Explore the words cloud of the CORolla project. It provides you a very rough idea of what is the project "CORolla" about.

solution    treatment    cardiovascular    people    aging    augmentation    trials    start    more    internal    women    manages    impaired    trial    trajectory    interatrial    clinical    accounting    complete    planning    elastic    frame    corassist    sme    ejection    hfpef    19    instrument    diastole    instrumental    individuals    market    prevalence    effect    validation    preserved    families    augment    life    hf    expanding    function    needing    financial    humans    threatening    ec    globally    economic    corolla    systole    occurs    dynamics    sales    total    device    spring    paragon    company    energy    health    social    fraction    metallic    drugs    animals    topcat    2021       25    though    invasive    minimally    time    procedure    implanted    filling    heart    harnesses    ago    national    treat    older    aligns    grant    inside    perfectly    shunting    first    reg    annually    congestive    contraction    diastolic    65    population    releases    introduces    self       million    ventricular    left    relaxation    form    vision    representing    world    patients   

Project "CORolla" data sheet

The following table provides information about the project.

Coordinator
CORASSIST CARDIOVASCULAR LTD 

Organization address
address: 114TH MORIYA AVE
city: HAIFA
postcode: 3461805
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www.corassist.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CORASSIST CARDIOVASCULAR LTD IL (HAIFA) coordinator 50˙000.00

Map

 Project objective

Heart Failure with preserved ejection fraction (HFpEF) is a life-threatening form of congestive heart failure condition annually affecting more than 25 million people globally. HFpEF occurs commonly in older individuals and has higher prevalence in women. As the European population is aging (over 65 accounting for 19.2% of the total European population, 2.4% more than 10 years ago), HFpEF will affect more and more people, representing significant economic and social challenge for the patients, their families and National Health Systems.

Currently there is no solution on the market for such heart failure condition. Though the effect of some drugs used in the treatment of HF with reduced ejection fraction are currently studied for HFpEF in large clinical trials (e.g. PARAGON-HF Trial, TOPCAT Study), a new approach based on the left interatrial shunting is needed.

The CorAssist introduces a “spring-like” metallic device, CORolla® for augmentation of diastolic function of the heart. The CORolla® is implanted inside the left ventricular of the heart in a minimally invasive procedure. The self-expanding, internal device harnesses the elastic energy during systole (contraction) state and releases it during diastole (relaxation) in order to augment dynamics of left ventricular relaxation and filling. CORolla® manages to impact directly and improve the impaired diastolic function, needing only one-time procedure.

CorAssist Cardiovascular has the vision to become the first company in the world to treat HFpEF. The EC grant is instrumental to this ambitious goal and company’s growth trajectory. Following a very promising validation in animals and humans, the company is planning to start first sales of CORolla® by the end of 2021.The SME Instrument project perfectly aligns with this objective, as it would provide the company with the financial resources necessary to complete the clinical study within the planned time-frame.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COROLLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COROLLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More